Centessa Pharmaceuticals plc (CNTA) has announced that it priced its underwritten public offering at roughly 10.81 million American Depositary Shares. Each of these shares symbolizes one ordinary share, and they are priced at $9.25 per share.
The company anticipates that the aggregate gross proceeds from this public offer will climax approximately to $100 million. This prediction excludes the deductions of underwriting discounts, commissions, and other expenses related to the offering.
Subject to meeting the standard closing conditions, the offering is projected to close around April 26, 2024.
Additionally, Centessa has given the underwriters the option to purchase up to an extra 1.62 million American Depositary Shares within a 30-day timeframe at the public offering price, deducting the underwriting discounts and commissions.
